

850 Town Center Drive, Suite 620  
Costa Mesa, CA 92626-1925  
Phone: (714) 708-8555  
Fax: (714) 708-8565

**Birch, Stewart,  
Kolasch & Birch, LLP**

APR 4 2005  
APR 04 2005

# Fax

**To:** Examiner David Saunders, Group 8992 **From:** Leonard R. Svensson  
**Fax:** (703) 872-9306 **Pages:** 13 including cover sheet  
**Phone:** **Date:** April 4, 2005  
**Your Ref.:** Application No. 09/902,174 **Our Ref.:** 0459-0636P  
**Re:** Response to Office Action **CC:**

☐ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (714) 708-8555, and send the original transmission to us by return mail at the address above.

◆ **Comments:**

Attached for filing are the following documents:

1. Large Entity Transmittal Form
2. Reply Under 37 C.F.R. § 1.111

APR 04 2005

**MS AMENDMENT**  
**PATENT**  
**0459-0636P**

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: LAURSEN, Inga et al. Conf.: 8992  
 Appl. No.: 09/902,174 Group: 1644  
 Filed: July 10, 2001 Examiner: SAUNDERS, David  
 For: PROCESS FOR PRODUCING IMMUNOGLOBULINS  
 FOR INTRAVENOUS ADMINISTRATION AND OTHER  
 IMMUNOGLOBULIN PRODUCTS

LARGE ENTITY TRANSMITTAL FORM**MS AMENDMENT**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

April 4, 2005

Sir:

Transmitted herewith is an amendment in the above-identified application.

☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

☒ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	17	-	20	=	0	\$50	\$0.00
INDEPENDENT	3	-	3	=	0	\$200	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$360	\$0.00
TOTAL							\$0.00

Appl. No. 09/902,174

- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ Check(s) in the amount of \$0.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,


BIRCH, STEWART, KOLASCH & BIRCH, LLP

  
Leonard R. Svensson, #30,330

LRS/lmt  
0459-0636P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment(s)

Certificate of Transmission  
I hereby Certify that this correspondence is being  
facsimile transmitted to the Patent and  
Trademark Office:  
On April 4, 2005  
Date  
  
Signature  
Lori M. Tillman  
Typed or printed name of person signing

FILED  
MAR 10 2005  
FBI/DOJ

APR 04 2005

PATENT  
0459-0636P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:	LAURSEN, Inga et al.	Conf.: 8992
Appl. No.:	09/902,174	Group: 1644
Filed:	July 10, 2001	Examiner: SAUNDERS, David
For:	PROCESS FOR PRODUCING IMMUNOGLOBULINS FOR INTRAVENOUS ADMINISTRATION AND OTHER IMMUNOGLOBULIN PRODUCTS	

REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 4, 2005

Sir:

In response to the Office Action dated January 4, 2005, the following amendments and remarks are respectfully submitted in connection with the above-identified application.